Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Lei, Ziying ^a   Mo, Zhishuo ^a   Zhu, Jianyun ^a   Pang, Xiuqing ^a   Zheng, Xingrong ^a   Wu, Zhebin ^a   Wang, Ke ^a   Li, Xinhua ^a   Xie, Dongying ^a   Gao, Zhiliang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BILIRUBIN; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 33; SOLUBLE ST2 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; CYTOKINE; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NORMAL VALUE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTHROMBIN TIME; SOLUBLE ST2 BLOOD LEVEL; SURVIVAL RATE; BIOPSY; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; IMMUNOASSAY; KAPLAN MEIER METHOD; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; BILIRUBIN; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; KAPLAN-MEIER ESTIMATE; LIVER; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928253863     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/535938     Document Type: Article

References (48)

1. H. E. Kohrt, D. L. Ouyang, and E. B. Keeffe, "Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection," Clinics in Liver Disease, vol. 11, no. 4, pp. 965-991, 2007.
2. G. Millonig,M. Kern,O. Ludwiczek, K. Nachbaur, and W. Vogel, "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening" World Journal of Gastroenterology, vol. 12, no. 6, pp. 974-976, 2006.
3. W.-H. Sheng, J.-H. Kao, P.-J. Chen et al., "Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy," Clinical Infectious Diseases, vol. 45, no. 9, pp. 1221-1229, 2007.
4. S. K. Sarin, A. Kumar, J. A. Almeida et al., "Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)," Hepatology International, vol. 3, no. 1, pp. 269-282, 2009.
5. Y. Miyake, Y. Iwasaki, A. Takaki et al., "Lamivudine treatment improves the prognosis of fulminant hepatitis B," Internal Medicine, vol. 47, no. 14, pp. 1293-1299, 2008.
6. J. Neuberger, "Prediction of survival for patients with fulminant hepatic failure," Hepatology, vol. 41, no. 1, pp. 19-22, 2005.
7. R. M. Merion, P. Sharma, A. K. Mathur, and D. E. Schaubel, "Evidence-based development of liver allocation: a review," Transplant International, vol. 24, no. 10, pp. 965-972, 2011.
8. P. S. Kamath and W. R. Kim, "The model for end-stage liver disease (MELD)," Hepatology, vol. 45, no. 3, pp. 797-805, 2007.
9. G. Ambrosino, A. Naso, P. Feltracco et al., "Cytokines and liver failure: modification of TNF-and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS)," Acta Biomedica, vol. 74, supplement 2, pp. 7-9, 2003.
10. E. Galun and J. H. Axelrod, "The role of cytokines in liver failure and regeneration: potential new molecular therapies," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1592, no. 3, pp. 345-358, 2002.
11. Z. Zou, B. Li, D. Xu et al., "Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection," Journal of Clinical Gastroenterology, vol. 43, no. 2, pp. 182-190, 2009.
12. Y. Masubuchi, S. Sugiyama, and T. Horie, "Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury," Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 273-279, 2009.
13. G. A. Roth, M. Zimmermann, B. A. Lubsczyk et al., "Upregulation of interleukin 33 and soluble ST2 serumlevels in liver failure," Journal of Surgical Research, vol. 163, no. 2, pp. e79-e83, 2010.
14. C. Moussion,N. Ortega, and J.-P. Girard, "TheIL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'Alarmin'" PLoS ONE, vol. 3, no. 10, Article ID e3331, 2008.
15. M. Lamkanfi and V. M. Dixit, "IL-33 raises alarm," Immunity, vol. 31, no. 1, pp. 5-7, 2009.
16. F. Belpinati, G. Malerba, E. Trabetti et al., "Association of childhood allergic asthma with markers flanking the IL33 gene in Italian families," Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 667-668, 2011.
17. M. Milovanovic,V. Volarevic, G. Radosavljevic et al., "IL-33/ST2 axis in inflammation and immunopathology," Immunologic Research, vol. 52, no. 1-2, pp. 89-99, 2012.
18. F. Y. Liew, "IL-33: a Janus cytokine," Annals of the Rheumatic Diseases, vol. 71, supplement 2, pp. i101-i104, 2012.
19. Z. Yang, Y. Liang, W. Xi, C. Li, and R. Zhong, "Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population," Clinical and Experimental Medicine, vol. 11, no. 2, pp. 75-80, 2011.
20. A. M. Miller, "Role of IL-33 in inflammation and disease," Journal of Inflammation, vol. 8, article 22, 2011.
21. S. Tominaga, "A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor," FEBS Letters, vol. 258, no. 2, pp. 301-304, 1989.
22. J. Schmitz, A. Owyang, E. Oldhamet al., "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines," Immunity, vol. 23, no. 5, pp. 479-490, 2005.
23. R. K. Kumar and P. S. Foster, "ST2: marker, activator and regulator ofTh2 immunity" Clinical and Experimental Allergy, vol. 32, no. 10, pp. 1394-1396, 2002.
24. A. Bhardwaj and J. L. Januzzi Jr., "ST2: a novel biomarker for heart failure," Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 459-464, 2010.
25. T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, and M. Haltmayer, "Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure," Clinical Chemistry, vol. 54, no. 4, pp. 752-756, 2008.
26. V. Volarevic, M. Mitrovic, M. Milovanovic et al., "Protective role of IL-33/ST2 axis in Con A-induced hepatitis," Journal of Hepatology, vol. 56, no. 1, pp. 26-33, 2012.
27. H. E. Wasmuth, D. Kunz, E. Yagmur et al., "Patients with acute on chronic liver failure display 'sepsis-like' immune paralysis," Journal of Hepatology, vol. 42, no. 2, pp. 195-201, 2005.
28. J. J. Hoogerwerf, M. W. T. Tanck, M. A. D. van Zoelen, X. Wittebole,P.-F. Laterre, and T. vanderPoll, "Soluble ST2plasma concentrations predictmortality in severe sepsis," Intensive Care Medicine, vol. 36, no. 4, pp. 630-637, 2010.
29. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, and Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association, "Diagnostic and treatment guidelines for liver failure (2012 version)," Zhonghua Gan Zang Bing Za Zhi, vol. 21, pp. 177-183, 2013.
30. V. Codices, C. Martins, C. Novo et al., "Dynamics of cytokines and immunoglobulins serumprofiles in primary and secondary Cryptosporidium parvum infection: usefulness of Luminex xMAPtechnology," Experimental Parasitology, vol. 133, no. 1,pp. 106-113, 2013.
31. Y. Jia, D.-N. Hu, and J. Zhou, "Human aqueous humor levels of TGF-beta 2: relationship with axial length," BioMed Research International, vol. 2014,Article ID 258591, 5 pages, 2014.
32. P. Marvie, M. Lisbonne, A. L'Helgoualc'h et al., "Interleukin-33 overexpression is associated with liver fibrosis in mice and humans," Journal of Cellular andMolecularMedicine, vol. 14,no. 6, pp. 1726-1739, 2010.
33. M. I. Arshad, M. Rauch, A. L'Helgoualc'h et al., "NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis," European Journal of Immunology, vol. 41, no. 8, pp. 2341-2348, 2011.
34. L. G. Guidotti and F. V. Chisari, "Immunobiology and pathogenesis of viral hepatitis," Annual Review of Pathology, vol. 1, pp. 23-61, 2006.
35. H. Malhi and G. J. Gores, "Cellular and molecular mechanisms of liver injury," Gastroenterology, vol. 134, no. 6, pp. 1641-1654, 2008.
36. W. V. Bonilla, A. Fröhlich, K. Senn et al., "The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses," Science, vol. 335, no. 6071, pp. 984-989, 2012.
37. T. Miyagaki, M. Sugaya, H. Yokobayashi et al., "High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection," Journal of Investigative Dermatology, vol. 131, no. 3, pp. 794-796, 2011.
38. K. Oshikawa, K. Yanagisawa, S. Tominaga, and Y. Sugiyama, "Expression and function of the ST2 gene in a murine model of allergic airway inflammation," Clinical and Experimental Allergy, vol. 32, no. 10, pp. 1520-1526, 2002.
39. L. Q. Chen, J. A. deLemos, S. R. Das, C. R. Ayers, and A. Rohatgi, "Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: theDallasHeart Study," Clinical Chemistry, vol. 59, no. 3, pp. 536-546, 2013.
40. C. Pan,Y. Gu,W. Zhang et al., "Dynamic changes of lipopolysaccharide levels in different phases of acute on chronic hepatitis B liver failure," PLoS ONE, vol. 7, no. 11,Article ID e49460, 2012.
41. D.-W. Han, "Intestinal endotoxemia as a pathogenetic mechanism in liver failure," World Journal of Gastroenterology, vol. 8, no. 6, pp. 961-965, 2002.
42. M. J. Sweet, B. P. Leung, D. Kang et al., "A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of toll-like receptor 4 expression," The Journal of Immunology, vol. 166, no. 11, pp. 6633-6639, 2001.
43. S. Kumar, M. N. Tzimas, D. E. Griswold, and P. R. Young, "Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli," Biochemical and Biophysical Research Communications, vol. 235, no. 3, pp. 474-478, 1997.
44. S. Saccani, N. Polentarutti, G. Penton-Rol, J. E. Sims, and A. Mantovani, "Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo," Cytokine, vol. 10, no. 10, pp. 773-780, 1998.
45. E. K. Brint,D. Xu,H. Liu et al., "ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance," Nature Immunology, vol. 5, no. 4, pp. 373-379, 2004.
46. F. Y. Liew, D. Xu, E. K. Brint, and L. A. J. O'Neill, "Negative regulation of toll-like receptor-mediated immune responses," Nature Reviews Immunology, vol. 5, no. 6, pp. 446-458, 2005.
47. T. Xing, L. Li, H. Cao, and J. Huang, "Altered immune function of monocytes in different stages of patients with acute on chronic liver failure," Clinical and Experimental Immunology, vol. 147, no. 1, pp. 184-188, 2007.
48. N. G. Sandler, C. Koh, A. Roque et al., "Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection," Gastroenterology, vol. 141, no. 4, pp. 1220-1230, 2011.